文献速递神经肿瘤

基因表达分析揭示CDC20与星形细胞瘤恶性进展及不良预后相关

CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression.
PubMed 文献 · J Neurooncol · 2017-04-21

该研究比较35例弥漫性星形细胞瘤(AIIs,WHO II级)、13例间变性星形细胞瘤(AAIIIs,WHO III级)和34例继发性胶质母细胞瘤(sGBMIVs,WHO IV级)共82例样本的平均表达水平,筛选出CDC20(p=0.0129)和PLK1(p=0.0046)与生存相关;qPCR、western blot和IHC验证CDC20和PLK1表达随级别升高;CDC20高表达与WHO分级、KPS、IDH1、PTEN和EGFR改变相关。

要点

  • CDC20(p=0.0129)和PLK1(p=0.0046)经统计学与Kaplan-Meier生存分析筛选为候选基因。
  • qPCR、western blot和IHC验证CDC20和PLK1表达水平随胶质瘤级别升高显著上升。
  • CDC20高表达与WHO分级(p<0.0001)、KPS(p<0.0001)、IDH1(p<0.0001)、PTEN(p=0.027)和EGFR扩增(p=0.048)相关。

核心结论

  • 研究证明CDC20表达水平随星形细胞瘤恶性进展和不良预后显著升高。

研究设计与样本

  • 研究比较82例样本(35例AIIs、13例AAIIIs和34例sGBMIVs)的平均表达水平,采用非配对student检验。
  • 通过DAVID和Kaplan-Meier生存分析筛选候选基因,并在不同级别胶质瘤中用实时PCR(qPCR)、western blot和免疫组化(IHC)验证显著候选基因。
  • 采用卡方分析分析目标基因与临床分子特征的相关性。

主要发现

  • CDC20(p=0.0129)和PLK1(p=0.0046)经统计和Kaplan-Meier生存分析筛选出。
  • 实时PCR(qPCR)、western blot和IHC显示CDC20和PLK1表达水平显著上升。
  • 卡方分析显示CDC20高表达患者与低表达患者在WHO分类(p<0.0001)、Karnofsky功能状态评分(KPS,p<0.0001)、异柠檬酸脱氢酶突变(IDH1,p<0.0001)、磷酸酶和张力蛋白同源物突变(PTEN,p=0.027)和表皮生长因子受体蛋白扩增(EGFR,p=0.048)方面存在差异。
  • 生物学过程分析表明CDC20可能在星形细胞增殖中起重要作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The malignant transformation of astrocytoma may result from the accumulation of multiple genetic alterations. Current research shows that diffuse astrocytoma (AIIs, WHO grade II) is inherently predisposed to recur locally, and to spontaneously progress to anaplastic astrocytoma (AAIIIs, WHO grade III) and eventually secondary glioblastoma (sGBMIVs, WHO grade IV). The aim of the study was to identify and validate the important gene(s) associated with malignant progression and poor prognosis of astrocytoma. Average expression levels of 82 samples (35 AIIs, 13 AAIIIs and 34 sGBMIVs) were compared to each other through no-paired student test. Candidate genes were screened by DAVID and Kaplan-Meier survival analysis. Further, the significant candidate genes were validated through real-time PCR(qPCR), western blot and immunohistochemistry (IHC) in different grades of glioma. Finally, the association of target gene and clinical molecular characterization was analyzed by Chi-squared analysis. The cell-division cycle protein 20(CDC20, p = 0.0129) and the polo-like kinase 1(PLK1, p = 0.0046) were screened by statistical and Kaplan-Meier survival analysis. The expression levels of CDC20 and PLK1 rose significantly through real-time PCR(qPCR), western blot and IHC. A chi-squared analysis showed that patients with CDC20 high-expression differ from patients with CDC20 low-expression in terms of WHO classification (p < 0.0001), karnofsky performance score (KPS, p < 0.0001), isocitrate dehydrogenase mutation (IDH1, p < 0.0001), phosphatase and tensin homolog mutation (PTEN, p = 0.027) and epidermal growth factor receptor protein amplification (EGFR, p = 0.048). Moreover, the biological processes analyses indicate CDC20 might have an essential role in astrocyte cell proliferation. We demonstrated that the expression level of CDC20 increases significantly along with malignant progression and poor prognosis of astrocytoma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ding Y, Yu S, Bao Z, et al. CDC20 with malignant progression and poor prognosis of astrocytoma revealed by analysis on gene expression. J Neurooncol. 2017. PMID: 28432586. doi:10.1007/s11060-017-2434-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。